Medical Director/ Senior Medical Director

Clinical Data Manager

Vice President, Clinical Development

1910 Genetics

20n Bio

3DBio Therapeutics

3T Biosciences

4D Molecular Therapeutics

64x Bio

76Bio

A-Alpha Bio

A2 Biotherapeutics

AAVogen

ACELYRIN

ADAXION Therapeutics

AI Proteins

AIRNA Bio

ALX Oncology

AN2 Therapeutics

AOA Dx

ARTBIO

AS2 Bio Inc

AUM BioTech

AVROBIO

Ab Studio

Abalone Bio

Abata Therapeutics

Abeona Therapeutics

Abintus Bio

Abiosciences

Absci

Accelevir Diagnostics

Accent Therapeutics

Acepodia

Achieve Life Sciences

Acomhal Research

Acrivon Therapeutics

Actym Therapeutics, Inc.

Acutis Diagnostics

Adaptive Phage Therapeutics

Adcentrx Therapeutics

Adicet Bio

Adiso Therapeutics

Aditum Bio

Admera Health

Adverum Biotechnologies

Aeglea BioTherapeutics

Aera Therapeutics

Aether Bio

Affini-T Therapeutics

Affinia Therapeutics

AgBiome

Agastiya Biotech

Agena Bioscience

AiViva Biopharma

Ainnocence

AivoCode

Aixa Bio

Akero Therapeutics

Akita Biosciences

Akouos

Akttyva Therapeutics

Alamar Biosciences

Aldebaran Therapeutics

Alector

Alida Biosciences

AlivaMab Discovery Services

Alkahest

Alladapt Immunotherapeutics

Allarta Life Science

Allay Therapeutics

AlloVir

Alloy Therapeutics

Alltrna

AlpaLifeBio

Alpha-9 Oncology

Alphabioregen

AltPep

Alterome Therapeutics

Altis Biosystems

Alto Neuroscience

Alumis

Alveo Technologies

Alveolus Bio

Alzheon

AmbAgon Therapeutics

Amberstone Biosciences

Amolyt Pharma

Amylyx Pharmaceuticals

AnHeart Therapeutics

Anagram Therapeutics

Ancora Biotech LLC

Andes

Andson Biotech

Anebulo Pharmaceuticals

Angiex

Angiocrine Bioscience

Anima Biotech

Ankyra

Annexon Biosciences

Anodyne Nanotech

Anokion

Ansa Biotechnologies

Biomea Fusion is developing novel small molecules to treat genetically defined diseases with high unmet need. Genetically defined diseases have biomarker-identifiable patient populations that Biomea can target with in silico designed small molecules with new mechanisms of action. This approach employs Biomea’s FUSIONTM System discovery platform that uses novel chemical scaffolds and a computational platform to produce optimized product profiles with high potency and safety. Biomea’s research and development has so far produced three novel, covalent inhibitor programs. Biomea recently received FDA clearance for IND application for their oral menin inhibitor, BMF-219, in type 2 diabetes. BMF-219 is also being developed as a cancer therapy.

Find a biotech startup job.